The information on this website is intended to provide scientific information about Alkermes products and areas of therapeutic interest. Information may include data on investigational uses of approved or unapproved drugs for which safety and effectiveness have not been established. There is no guarantee that such uses will receive health authority approval and Alkermes does not recommend or suggest use of its medicines in a manner inconsistent with approved labeling.
Studies designed, executed and funded by Alkermes, Inc.
Showing 10 of 99 results
Sort by date:
Ascending
Mar 2023
Reduction in Multiple Cardiometabolic Risk Factors With Combined Olanzapine/Samidorphan Compared With Olanzapine: Post Hoc Analyses From a 24-Week Phase 3 Study
Schizophrenia Bulletin
AUTHOR(S)
May 2023
Opioid antagonism mitigates antipsychotic-associated weight gain: focus on olanzapine
CNS Spectrums
AUTHOR(S)
Jul 2023
Olanzapine/samidorphan combination consistently mitigates weight gain across various subgroups of patients
CNS Spectrums
AUTHOR(S)
Aug 2023
Clinical, Economic, and Humanistic Outcomes Associated with Obesity Among People with Bipolar I Disorder in the United States: Analysis of National Health and Wellness Survey Data
ClinicoEconomics and Outcomes Research
AUTHOR(S)
Jan 2024
Treatment Journey and Healthcare Resource Use Among Patients With Alcohol Use Disorder Who Initiated Extended-Release Naltrexone: An Analysis of Veterans Affairs Data
Substance Use: Research and Treatment
AUTHOR(S)
Jan 2024
Functioning and Cognition in Patients with Schizophrenia After Initiating Treatment with Aripiprazole Lauroxil: Secondary Outcomes and Post Hoc Analysis
Innovations in Clinical Neuroscience
AUTHOR(S)
Feb 2024
Safety and Tolerability of Starting Aripiprazole Lauroxil With Aripiprazole Lauroxil NanoCrystal Dispersion in 1 Day Followed by Aripiprazole Lauroxil Every 2 Months Using Paliperidone Palmitate Monthly as an Active Control in Patients With Schizophrenia
Journal of Clinical Psychiatry
AUTHOR(S)
Jul 2024
Using qualitative exit interviews to explore schizophrenia burden and treatment experience in clinical trial patients
Frontiers in Psychiatry
AUTHOR(S)
Jul 2024
Initiating Aripiprazole Lauroxil: Post Hoc Analysis of Safety and Tolerability of 1-Day and 21-Day Regimens
The Journal of Clinical Psychiatry
AUTHOR(S)
Aug 2024
Preferences for attributes of oral antipsychotic treatments: results from a discrete-choice experiment in respondents with schizophrenia or bipolar I disorder
BMC Psychiatry
AUTHOR(S)
